Related Experiment Videos
Fibronectin as a predictor of preeclampsia: a pilot study
I Jones1, D Cowley, M Andersen
1Department of Obstetrics and Gynaecology, University of Queensland, South Brisbane.
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|February 1, 1996
Summary
Serum fibronectin levels measured between 25-30 weeks gestation can identify women at risk for preeclampsia. A single test at 28 weeks gestation appears most suitable for screening in this pilot study.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Biochemistry
Background:
- Preeclampsia is a significant complication of pregnancy.
- Early identification of preeclampsia risk is crucial for timely intervention.
- Serum biomarkers are being investigated for pregnancy complication screening.
Purpose of the Study:
- To evaluate serum fibronectin levels as a potential biomarker for preeclampsia.
- To determine the optimal gestational age for single-time point fibronectin measurement for preeclampsia screening.
Main Methods:
- Serum fibronectin levels were measured using nephelometry in pregnant women.
- Participants were assessed between 25-30 weeks' gestation.
- Women were categorized as normotensive or developing preeclampsia.
Main Results:
- Serum fibronectin levels differentiated between women who remained normotensive and those who developed preeclampsia.
- A single measurement at 28 weeks' gestation showed promise as a screening time point.
Conclusions:
- Serum fibronectin measurement may serve as a useful screening tool for preeclampsia.
- Further research is needed to validate reliability, predictability, and cost-effectiveness.
- 28 weeks' gestation is suggested as a potentially optimal time for a single screening test.